JP2010511669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511669A5 JP2010511669A5 JP2009539739A JP2009539739A JP2010511669A5 JP 2010511669 A5 JP2010511669 A5 JP 2010511669A5 JP 2009539739 A JP2009539739 A JP 2009539739A JP 2009539739 A JP2009539739 A JP 2009539739A JP 2010511669 A5 JP2010511669 A5 JP 2010511669A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- het
- compound according
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 31
- -1 hydroxy, mercapto Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 125000002757 morpholinyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000035143 Bacterial infection Diseases 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 239000002585 base Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 125000005418 aryl aryl group Chemical group 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 1
- 125000000815 N-oxide group Chemical group 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 238000000844 transformation Methods 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 *C(C(*)(C*CN)O)c1c(*)c2ccccc2nc1* Chemical compound *C(C(*)(C*CN)O)c1c(*)c2ccccc2nc1* 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125510.5 | 2006-12-06 | ||
| EP06125510 | 2006-12-06 | ||
| PCT/EP2007/063314 WO2008068268A1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010511669A JP2010511669A (ja) | 2010-04-15 |
| JP2010511669A5 true JP2010511669A5 (enExample) | 2010-11-18 |
| JP5466012B2 JP5466012B2 (ja) | 2014-04-09 |
Family
ID=37909392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539739A Active JP5466012B2 (ja) | 2006-12-06 | 2007-12-04 | 抗菌性キノリン誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8293732B2 (enExample) |
| EP (1) | EP2099760B1 (enExample) |
| JP (1) | JP5466012B2 (enExample) |
| KR (3) | KR20170003741A (enExample) |
| CN (1) | CN101547905B (enExample) |
| AP (1) | AP2670A (enExample) |
| AR (1) | AR064147A1 (enExample) |
| BR (1) | BRPI0719939B8 (enExample) |
| CA (1) | CA2668517C (enExample) |
| CL (1) | CL2007003515A1 (enExample) |
| CY (1) | CY1114384T1 (enExample) |
| DK (1) | DK2099760T3 (enExample) |
| EA (1) | EA022344B1 (enExample) |
| ES (1) | ES2407824T3 (enExample) |
| HR (1) | HRP20130372T1 (enExample) |
| IL (2) | IL199078A (enExample) |
| JO (1) | JO2970B1 (enExample) |
| ME (1) | ME01521B (enExample) |
| MX (1) | MX2009005979A (enExample) |
| MY (1) | MY150411A (enExample) |
| NO (1) | NO342095B1 (enExample) |
| NZ (1) | NZ577128A (enExample) |
| PL (1) | PL2099760T3 (enExample) |
| PT (1) | PT2099760E (enExample) |
| RS (1) | RS52753B (enExample) |
| SG (1) | SG10201405650SA (enExample) |
| SI (1) | SI2099760T1 (enExample) |
| TW (1) | TWI396536B (enExample) |
| UA (1) | UA101306C2 (enExample) |
| WO (1) | WO2008068268A1 (enExample) |
| ZA (1) | ZA200903946B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| CA3016068C (en) * | 2016-03-07 | 2024-02-27 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998018326A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| US6103905A (en) | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| WO2005070924A1 (en) | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Substituted quinolines and their use as mycobacterial inhibitors |
| WO2005070430A1 (en) | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Quinoline derivatives and use thereof as mycobacterial inhibitors |
| ES2306098T3 (es) | 2004-01-29 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de quinolina para uso como inhibidores de micobacterias. |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| ME02935B (me) | 2004-09-28 | 2018-04-20 | Janssen Pharmaceutica Nv | Vezujući domen bakterijske atp sintaze |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| EE05697B1 (et) | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
| JO2752B1 (en) | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| DK1898909T3 (en) | 2005-06-28 | 2017-02-06 | Janssen Pharmaceutica Nv | QUINOLIN DERIVATIVES AS ANTIBACTERIAL AGENTS |
| JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
-
2007
- 2007-11-29 JO JO2007505A patent/JO2970B1/en active
- 2007-12-04 AP AP2009004871A patent/AP2670A/xx active
- 2007-12-04 WO PCT/EP2007/063314 patent/WO2008068268A1/en not_active Ceased
- 2007-12-04 SG SG10201405650SA patent/SG10201405650SA/en unknown
- 2007-12-04 NZ NZ577128A patent/NZ577128A/en unknown
- 2007-12-04 BR BRPI0719939A patent/BRPI0719939B8/pt active IP Right Grant
- 2007-12-04 CA CA2668517A patent/CA2668517C/en active Active
- 2007-12-04 EP EP07847812A patent/EP2099760B1/en active Active
- 2007-12-04 JP JP2009539739A patent/JP5466012B2/ja active Active
- 2007-12-04 KR KR1020167037101A patent/KR20170003741A/ko not_active Ceased
- 2007-12-04 MX MX2009005979A patent/MX2009005979A/es active IP Right Grant
- 2007-12-04 CN CN200780044895.7A patent/CN101547905B/zh active Active
- 2007-12-04 PL PL07847812T patent/PL2099760T3/pl unknown
- 2007-12-04 ME MEP-2013-43A patent/ME01521B/me unknown
- 2007-12-04 ES ES07847812T patent/ES2407824T3/es active Active
- 2007-12-04 SI SI200731214T patent/SI2099760T1/sl unknown
- 2007-12-04 HR HRP20130372TT patent/HRP20130372T1/hr unknown
- 2007-12-04 US US12/516,249 patent/US8293732B2/en active Active
- 2007-12-04 RS RS20130165A patent/RS52753B/sr unknown
- 2007-12-04 DK DK07847812.0T patent/DK2099760T3/da active
- 2007-12-04 EA EA200970536A patent/EA022344B1/ru unknown
- 2007-12-04 MY MYPI20092286 patent/MY150411A/en unknown
- 2007-12-04 KR KR1020157031291A patent/KR101908350B1/ko active Active
- 2007-12-04 KR KR1020097012242A patent/KR101574642B1/ko active Active
- 2007-12-04 UA UAA200904217A patent/UA101306C2/ru unknown
- 2007-12-04 PT PT78478120T patent/PT2099760E/pt unknown
- 2007-12-05 AR ARP070105440A patent/AR064147A1/es unknown
- 2007-12-05 CL CL200703515A patent/CL2007003515A1/es unknown
- 2007-12-05 TW TW096146215A patent/TWI396536B/zh active
-
2009
- 2009-06-02 IL IL199078A patent/IL199078A/en active IP Right Grant
- 2009-06-05 ZA ZA200903946A patent/ZA200903946B/xx unknown
- 2009-07-06 NO NO20092536A patent/NO342095B1/no unknown
-
2013
- 2013-05-17 CY CY20131100403T patent/CY1114384T1/el unknown
-
2015
- 2015-09-10 IL IL241548A patent/IL241548B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511668A5 (enExample) | ||
| TWI606044B (zh) | 喹啉酮化合物 | |
| JP2010511667A5 (enExample) | ||
| JP2024522345A (ja) | ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体 | |
| JP4484703B2 (ja) | キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用 | |
| ES2333730T3 (es) | Derivados de quinolina y uso de los mismos como inhibidores de micobacterias. | |
| Khalaj et al. | Discovery of a novel nitroimidazolyl–oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation | |
| Nagawade et al. | Synthesis of new series of 1-Aryl-1, 4-dihydro-4-oxo-6-methyl pyridazine-3-carboxylic acid as potential antibacterial agents | |
| CA2632194A1 (en) | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
| AU2004262897B2 (en) | Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders | |
| JP2009503024A5 (enExample) | ||
| JP2010511669A5 (enExample) | ||
| JP2006504658A5 (enExample) | ||
| CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| JP2008500992A5 (enExample) | ||
| TW200418871A (en) | C-4"-substituted macrolide derivatives | |
| KR102470319B1 (ko) | 항균성 화합물 | |
| JP2009503025A5 (enExample) | ||
| JP2010511671A5 (enExample) | ||
| JP2017523213A (ja) | 抗菌薬としてのキノロン誘導体 | |
| TW202337455A (zh) | Ｒａｆ激酶抑制劑及其使用方法 | |
| JP2010511670A5 (enExample) | ||
| RU2009125520A (ru) | Антибактериальные хинолиновые производные | |
| JP2010511672A5 (enExample) | ||
| CN102245603A (zh) | 抗细菌感染的2-(哌啶-1-基)-4-唑基-噻唑-5-羧酸衍生物 |